ALAMEDA, Calif.–(BUSINESS WIRE)–Mar. 26, 2025– Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of…Original Article
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
